Molecular Templates, Inc. (MTEM): Price and Financial Metrics

Molecular Templates, Inc. (MTEM)

Today's Latest Price: $11.79 USD

0.74 (6.70%)

Updated Jan 19 4:00pm

Add MTEM to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MTEM Stock Summary

  • Of note is the ratio of Molecular Templates Inc's sales and general administrative expense to its total operating expenses; only 11.5% of US stocks have a lower such ratio.
  • With a price/sales ratio of 25.63, Molecular Templates Inc has a higher such ratio than 91.41% of stocks in our set.
  • With a year-over-year growth in debt of 103.7%, Molecular Templates Inc's debt growth rate surpasses 88.52% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Molecular Templates Inc, a group of peers worth examining would be CRBP, KALV, NXTC, DTIL, and ORMP.
  • MTEM's SEC filings can be seen here. And to visit Molecular Templates Inc's official web site, go to

MTEM Stock Price Chart Interactive Chart >

Price chart for MTEM

MTEM Price/Volume Stats

Current price $11.79 52-week high $19.12
Prev. close $11.05 52-week low $7.51
Day low $11.06 Volume 301,180
Day high $12.05 Avg. volume 266,878
50-day MA $9.61 Dividend yield N/A
200-day MA $12.27 Market Cap 589.08M

Molecular Templates, Inc. (MTEM) Company Bio

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is based in Austin, Texas.

MTEM Latest News Stream

Event/Time News Detail
Loading, please wait...

MTEM Latest Social Stream

Loading social stream, please wait...

View Full MTEM Social Stream

Latest MTEM News From Around the Web

Below are the latest news stories about Molecular Templates Inc that investors may wish to consider to help them evaluate MTEM as an investment opportunity.

Molecular Templates updates on study of MT5111, plans breast cancer expansion cohort in 1H21

Molecular Templates (MTEM) provides an update on the Phase 1 study for MT5111, a HER2 targeted engineered toxin bodies ((ETB)). To date, 16 study subjects have been treated in the dose escalation portion of this study. Five cohorts (0.5, 1.0, 2.0, 3.0, and 4.5 μg/kg/week) have been successfully completed and the...

Seeking Alpha | December 22, 2020

Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study

Phase 1 Study Dose Escalation Ongoing in All HER2 Positive Tumor Types HER2 Positive Breast Cancer Expansion Cohort Planned to be Initiated in 1H21 Expansion Cohorts in Additional Tumors Types to Begin When MTD or Recommended Phase 2 Dose is ReachedAUSTIN, Texas, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today provided an update on the Phase 1 study for MT5111, MTEM’s HER2 targeted ETB.To date, 16 study subjects have been treated in the dose escalation portion of this study. Five cohorts (0.5, 1.0, 2.0, 3.0, and 4.5 μg/kg/week) have been succ...

Yahoo | December 21, 2020

Is MTEM A Good Stock To Buy Now According To Hedge Funds?

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]

Yahoo | December 19, 2020

Molecular Templates, Inc. (NASDAQ:MTEM) Major Shareholder Purchases $1,077,500.00 in Stock

Molecular Templates, Inc. (NASDAQ:MTEM) major shareholder Target N. V. Biotech purchased 125,000 shares of the business’s stock in a transaction on Wednesday, December 9th. The shares were acquired at an average price of $8.62 per share, with a total value of $1,077,500.00. Following the completion of the transaction, the insider now owns 6,060,331 shares of […]

Watchlist News | December 14, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molecular Templates, Inc. - MTEM

NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Molecular Templates, Inc. (“Molecular” or the “Company”) (NASDAQ: MTEM).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.  The investigation concerns whether Molecular and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On November 6, 2020, Molecular Templates disclosed that the U.S. Food and Drug Administration (“FDA”) had placed the Company’s “MT-3724 clinical studies on partial clinical hold following a treatment-related fatality in one subject who experienced Grade 5 capillary leak syndrome i...

Yahoo | December 1, 2020

Read More 'MTEM' Stories Here

MTEM Price Returns

1-mo 22.18%
3-mo 23.07%
6-mo -5.98%
1-year N/A
3-year -0.76%
5-year 206.23%
YTD 25.56%
2020 -32.86%
2019 246.16%
2018 -59.68%
2017 107.02%
2016 -8.33%

Continue Researching MTEM

Want to see what other sources are saying about Molecular Templates Inc's financials and stock price? Try the links below:

Molecular Templates Inc (MTEM) Stock Price | Nasdaq
Molecular Templates Inc (MTEM) Stock Quote, History and News - Yahoo Finance
Molecular Templates Inc (MTEM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9031 seconds.